What Keeps Noradrenaline Tablets Below Content Uniformity Failure Limits?

Direct compression of noradrenaline veterinary grade API into low-dose tablets is governed by blend uniformity rather than dry-state chemical stability alone. At a target dose of 0.05–0.50 mg base equivalent per unit, the active is pre-blended with lactose monohydrate or mannitol at a 1:10 ratio and passed through a 500 µm stainless steel sieve before final blending. The final tablet mass is typically 80–150 mg and contains microcrystalline cellulose 35–45% w/w, dibasic calcium phosphate anhydrous 20–30% w/w, crospovidone 2–4% w/w, and sodium stearyl fumarate 0.5–1.0% w/w. Compression on a rotary tablet press is performed at 15–30 rpm with main compression force 8–12 kN, producing hardness 40–70 N and friability ≤1.0% per Ph. Eur. 2.9.7. Disintegration in water at 37 °C is ≤15 min per Ph. Eur. 2.9.1. The processing environment is maintained at 20–25 °C and ≤35% RH; above 60% RH, excipients are pre-dried at 40 °C for 4 h because residual moisture accelerates oxidative discoloration in the presence of trace metal ions. Packaging in cold-formed aluminium foil blisters with 0.5 g silica gel desiccant is used for moisture-sensitive tablets. Dissolution testing according to USP 711 uses Apparatus 2 at 50 rpm in 900 mL phosphate buffer pH 4.5 containing 0.1% w/v sodium metabisulfite; acidic media below pH 2.0 are avoided because acid-catalysed degradation increases and assay recovery falls. Because oral systemic bioavailability is limited by extensive first-pass metabolism, tablet use is confined to local mucosal protocols, experimental pharmacology, or species-specific enteral delivery where pharmacokinetic data exist; published data for this specific configuration is limited.

Noradrenaline veterinary grade API as noradrenaline tartrate is formulated into injectable solutions at 0.02–0.20 mg/mL base equivalent for constant-rate infusion in anesthetized or critically ill non-food animals. The aqueous system is buffered to pH 3.5–4.0 with 0.01–0.05 M citrate buffer because the catechol ring undergoes pH-dependent autoxidation; above pH 5.5, quinone formation accelerates and visible discoloration appears within 24–48 h at 25 °C when dissolved oxygen exceeds 1.0 mg/L. Sodium metabisulfite is added at 0.1–0.5 mg/mL as oxygen scavenger, and the headspace is flushed with pharmaceutical-grade nitrogen until residual oxygen by polarographic probe is ≤1.0% v/v. Tonicity is adjusted with sodium chloride to 285–310 mOsm/kg by freezing-point depression per USP 785. The solution is passed through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane under aseptic conditions; terminal steam sterilization at 121 °C for 15 min is avoided because thermal oxidation of the catechol group produces adrenochrome-type degradation products. If terminal sterilization is used, a 115 °C 20 min cycle may be considered only after forced-degradation data establish total degradation ≤5.0%; published data for this specific configuration is limited. The finished solution is stored in Type I borosilicate glass vials with light-protective secondary packaging because photolysis under 365 nm UVA irradiation increases dimer formation. In-use dilution in 0.9% sodium chloride or 5% glucose is used for infusion; non-PVC polyolefin tubing is preferred because flexible PVC containing di(2-ethylhexyl) phthalate shows measurable sorption and plasticizer-dependent oxidative incompatibility. Co-infusion with alkaline solutions such as sodium bicarbonate 8.4% is contraindicated because the resulting pH shift above 6.0 accelerates oxidation and reduces effective concentration.

Low-Dose Capsule Filling and Moisture Exclusion

Hard gelatin capsule filling of noradrenaline tartrate is performed in a low-moisture filling suite at 22–25 °C and ≤40% RH. A direct-fill formulation contains lactose monohydrate 80–90% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.5% w/w, with the active ingredient pre-dispersed at 1:10 in a non-hygroscopic filler. Capsule size is selected to keep fill weight 120–180 mg in a size 3 or size 4 shell. Residual water above 6.0% w/w in the fill mass migrates to the gelatin shell, inducing cross-linking and delayed disintegration; molecular sieve desiccant sachets are therefore placed in the immediate container. Dissolution testing is carried out with USP 711 Apparatus 2 at 50 rpm in 900 mL phosphate buffer pH 4.5 with 0.1% w/v sodium metabisulfite to prevent oxidative loss during the sampling window. For capsules containing 0.05–0.30 mg base equivalent, content uniformity follows USP 905 or Ph. Eur. 2.9.40 with acceptance value ≤15. Storage at 2–8 °C with light protection reduces shell hardening and active degradation; photoprotective packaging is required because noradrenaline in capsule powder exposed to UVA shows discoloration within days. Published data for this specific configuration is limited, so acceptance criteria must be justified by target-species pharmacokinetic data.

Dry powder blends intended for extemporaneous reconstitution or nasogastric administration avoid reducing sugars because the secondary amine of noradrenaline reacts with lactose under residual moisture to form brown Maillard-type adducts. Mannitol is used as the primary diluent at 1:100 or 1:200 active-to-diluent ratio; the active ingredient is first passed through a 180 µm screen and blended by geometric dilution with a tumble mixer at 25 rpm for 20 min. Loss on drying is maintained at ≤1.0% w/w using Karl Fischer titration per Ph. Eur. 2.5.12. Powder flow is measured by shear cell per ASTM D6128-16; the flow function coefficient is typically 4–10, which is acceptable for volumetric filling. The powder is filled into amber glass vials under nitrogen headspace and stored at 2–8 °C. For reconstitution, preservative-free 0.9% sodium chloride is added to produce a 40 µg/mL base-equivalent solution; the resulting solution is protected from light and used within 24 h at 2–8 °C. If the powder is intended for sterile use, it is sterilized by validated irradiation or prepared under aseptic conditions; terminal autoclaving of the dry powder is not appropriate because high temperature and residual moisture promote hydrolysis. Analytical verification uses ion-pair reversed-phase HPLC with electrochemical detection; the limit of quantification is set at 0.01 µg/mL for the reconstituted solution. Incompatibility with metal oxides, calcium carbonate, and alkaline buffers is considered during compounding; edetate disodium at 0.01% w/v may be added to the reconstitution vehicle to chelate trace iron and copper ions.

When Granulation Solvent Selection Determines API Recovery

Noradrenaline tartrate granules for veterinary solid dosage forms are produced preferentially by dry granulation because water-based wet granulation exposes the catechol to oxidative risk and prolonged heat. Roller compaction is performed with roll force 30–50 kN, gap 1.0–2.0 mm, and screen size 0.8 mm. The resulting granules show bulk density 0.55–0.70 g/mL and loss on drying ≤2.0% w/w. If wet granulation is unavoidable, the granulating fluid should be a hydroalcoholic solution containing 25% v/v water and 75% v/v ethanol, with povidone K30 at 3–5% w/w of dry mass and sodium metabisulfite at 0.05% w/w as oxygen scavenger. Granulation in a high-shear mixer at impeller tip speed 4–8 m/s and chopper speed 1500 rpm for 120 s is followed by wet milling through a 1.0 mm screen and fluid-bed drying at inlet air 40 ± 2 °C with dew point ≤5 °C. Drying is stopped when loss on drying reaches ≤2.0%; residual ethanol by headspace gas chromatography per Ph. Eur. 2.2.28 is controlled to ≤0.5%. Granule fraction between 125–1000 µm should be ≥80% by sieve analysis per Ph. Eur. 2.9.12. API recovery in the granule is verified at 98–102% of label claim by HPLC. Edetate disodium at 0.01% w/w is included in the granulating fluid to chelate trace metal ions. Granules are then compressed into tablets or filled into capsules; granulation improves content uniformity compared with direct compression at doses below 0.1 mg. Published data for this specific configuration is limited, and process validation must include forced-degradation controls for the chosen solvent system.

Premix manufacture for medicated feed containing noradrenaline veterinary grade API requires an explicit regulatory review under the target jurisdiction because noradrenaline is not listed as a feed additive for production animals in the EU Register of Feed Additives and extralabel feed use is prohibited in many countries. Where a national competent authority permits preparation for non-food animals under veterinary prescription, the premix carrier is selected to maintain pH 6.0–7.0 and water activity ≤0.6; ground oat hulls, cellulose, or wheat middlings are preferred over calcium carbonate because the alkaline surface of calcium carbonate raises local pH above 8.0 and accelerates catechol oxidation. Sodium metabisulfite at 0.2% w/w of the premix is incorporated as antioxidant, and the mixture is blended in a ribbon mixer at 20 rpm for 15–20 min. Homogeneity is assessed by sampling 10 points across the mixer discharge; the coefficient of variation should be ≤5% for the active assay if the premix is intended for uniform distribution in final feed, consistent with medicated feed homogeneity expectations under Regulation (EU) 2019/4. Because the active is highly potent and light-sensitive, the premix is packaged in opaque multi-wall bags with a moisture barrier layer and stored at 25 °C or below. Published stability data for noradrenaline in feed matrices are limited; any assigned shelf life must be generated under VICH stability guidance using the actual final feed matrix and target species exposure scenario. Analytical determination in feed requires extraction with acidic aqueous solution containing 0.1% w/v sodium metabisulfite, cleanup by solid-phase extraction, and quantification by liquid chromatography coupled to tandem mass spectrometry; method validation follows ISO 17025 requirements for in-house methods.

Oral, Nasogastric, and Topical Solution Stability Constraints

Non-sterile solutions of noradrenaline veterinary grade API for oral, nasogastric, or topical veterinary use are prepared at 0.05–0.1 mg/mL base equivalent in citric acid/sodium citrate buffer pH 3.5–4.0. Sodium metabisulfite is included at 0.05–0.1% w/v and edetate disodium at 0.01% w/v to suppress metal-catalysed oxidation. Preservative selection is species-specific: benzyl alcohol is avoided in cats because of neurotoxicity risk, and preservative-free single-use containers are preferred for neonatal patients; in multi-dose oral solutions for dogs, methylparaben at 0.1% w/v may be used only where target-species safety data support the choice. The solution is filtered through a 0.45 µm polyethersulfone membrane to remove particulate matter and filled into amber polyethylene terephthalate bottles; container light transmission is specified at ≤10% across 290–500 nm to limit photolytic degradation. Microbial quality for oral use follows Ph. Eur. 5.1.4 category 3; the total aerobic microbial count limit is 10³ CFU/g and the total yeast and mould count limit is 10² CFU/g. In-use stability after first opening is not assumed; any assigned holding time is justified by real-time data at 2–8 °C. Topical solution formulations are protected from light and alkalinizing agents; pH adjustment above 5.5 during compounding leads to rapid discoloration and loss of potency. Aqueous solutions are incompatible with strong oxidising agents, ferric chloride, and alkaline buffers; visual inspection alone is insufficient for release, so HPLC with electrochemical detection is used to quantify noradrenaline and the primary oxidation product to confirm that the degradation product level remains below the validated threshold.